Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

NCT05049681 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

234

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

DRUG: Camrelizumab
DRUG: Apatinib

Sponsor

Feng Wang